[{"indications": "Indications\u00a0management of symptoms of opioid withdrawal", "name": "LOFEXIDINE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.10 Drugs used in substance dependence", "4.10.3 Opioid dependence", "Adjunctive therapy and symptomatic treatment"], "cautions": "Cautions\u00a0severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, bradycardia, hypotension (monitor pulse rate and blood pressure); history of QT prolongation, concomitant administration of drugs that prolong QT interval; metabolic disturbances; withdraw gradually over 2\u20134 days (or longer) to minimise\r\nrisk of rebound hypertension and associated symptoms; depression; interactions: Appendix\r\n1 (lofexidine)", "side-effects": "Side-effects\u00a0dry mucous membranes; hypotension, bradycardia;\r\ndizziness, drowsiness; QT-interval prolongation also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3699.htm", "doses": ["adult and child over 12 years, initially 800\u00a0micrograms daily\r\nin divided doses, increased as necessary in steps of 400\u2013800\u00a0micrograms\r\ndaily to max. 2.4\u00a0mg daily in divided doses; max. single dose 800\u00a0micrograms;\r\nrecommended duration of treatment 7\u201310 days if no opioid use (but\r\nlonger may be required)"], "pregnancy": "Pregnancy\u00a0use only if benefit outweighs risk\u2014no information\r\navailable"}]